[Effect of 3-oxypyridine and succinic acid derivatives on affective status in recrudescence of inflammatory diseases of uterus and its appendages]

RCT OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-25 ⓘ

In a randomized trial of females with recurrent uterine inflammatory diseases, emoxipin, reamberin, and mexidol reduced depression, anxiety, and systemic inflammation, with mexidol showing the greatest efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Short-term, prospective placebo-controlled simple blind randomized study of the effects of 3-oxypyridine and succinic acid derivatives (emoxipin, reamberin, mexidol) on the affective status of females with recrudescence of the inflammatory diseases of uterus and its appendages (IDUA) in comparison to changes of systemic inflammatory response (SIR) markers level in the blood has been conducted. It is established that the inclusion of emoxipin, reamberin and mexidol in complex treatment of IDUA recrudescence reduce depression, anxiety and SIR laboratory signs. Mexidol being both 3-oxypyridine and succinic acid derivative showed the best influence on the dynamics of affective disorders and SIR changes.

My notes (saved in your browser only)

MeSH descriptors

Depressive Disorder Genital Diseases, Female Picolines Pyridines Succinic Acid Adnexa Uteri Adnexa Uteri Adnexa Uteri Adolescent Adult Antioxidants Antioxidants Antioxidants Brain Brain Brain Depressive Disorder Depressive Disorder Depressive Disorder Female

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:11:19.299510+00:00
License: CC0 · commercial use OK